Since mTOR inhibitors are in general well tolerated and demonstrated at least partial efficacy in relapsed DLBCL patients, we investigated whether mTOR inhibition is sufficient to prevent the reactivation of S6 phosphorylation in AZD8186-treated DLBCL cell lines [32–34]. This evidence concerns the gene MTOR and diffuse large B-cell lymphoma.